About this trial
The goal of this study is to conduct a prospective trial implementing a modified version of the Emory Protocol for administering ANG II to patients with post cardiac bypass vasoplegia. The main questions we aim to answer are: 1.) does administration of improve mortality, 2.) does the administration of Ang II using the modified protocol shorten the time needed to reach optimal MAP, 3.) does the administration of Ang II using the modified protocol shorten length of stay in the ICU and hospital? Researchers will compare outcomes from the interventional group to historical controls who did not receive Ang II using the modified protocol.
Eligibility criteria
Qualifiers
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged 18 or over
Exhibiting vasoplegia or vasoplegic shock following surgeries involving cardiopulmonary bypass
Disqualifiers
Current use of angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs)
Presence of treatment with high-dose glucocorticoids
Pregnancy or lactation
Known allergic reactions to components of the Giapreza, <specify components/allergens>
Trial design
Treatments tested in this trial
- Angiotensin II (Giapreza®)